Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fezagepras - Liminal BioSciences

Drug Profile

Fezagepras - Liminal BioSciences

Alternative Names: PBI 4050; Setogepram - Liminal BioSciences

Latest Information Update: 04 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ProMetic Life Sciences
  • Developer Liminal BioSciences
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Hepatoprotectants; Phenylacetates; Skin disorder therapies; Small molecules
  • Mechanism of Action Ammonia scavengers; AMP activated protein kinase modulators; Autophagy stimulants; Cell differentiation modulators; Colony stimulating factor stimulants; Cytokine modulators; Erythropoiesis stimulants; Extracellular matrix protein inhibitors; FFAR1 protein stimulants; GPR84 protein antagonists; Immunomodulators; Inflammation mediator inhibitors; MTOR protein inhibitors; MTOR protein modulators; PPAR alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn genetic disorders; Idiopathic pulmonary fibrosis; Alstrom's Syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute lung injury; Alstrom's Syndrome; Anaemia; Cystic fibrosis; Diabetic nephropathies; Haematological disorders; Hyperammonaemia; Hypertriglyceridaemia; Idiopathic pulmonary fibrosis; Liver disorders; Metabolic syndrome; Neutropenia; Non-alcoholic fatty liver disease; Pulmonary hypertension; Renal fibrosis; Scleroderma; Type 2 diabetes mellitus

Most Recent Events

  • 29 Jul 2022 Liminal BioSciences terminates a phase Ia trial in Hyperammonaemia (In volunteers) in United Kingdom, due to discontinuation of drug development by company (PO) (NCT05349435)
  • 29 Jul 2022 Discontinued - Phase-I for Hyperammonaemia (In the elderly, In volunteers, In adults) in United Kingdom (PO)
  • 21 Jul 2022 Liminal Biosciences terminates a phase II/III trial in Idiopathic pulmonary fibrosis prior to enrolment due to discontinuation of drug development by company (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top